미국 · 보도자료 · Ultragenyx Pharmaceutical Inc. · 2026-10-02 06:00
MPS IIIA 유전자 치료제 최초로 유럽 EMA 판매 허가 신청 제출
BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene etisparvovec, for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A.
Ultragenyx Pharmaceutical Inc. 다른 공시·급등 이유 보기 · GK의 공시레이더 — 미국·한국 실시간 공시
